Clinical Trial

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Study acronym: CR-SEQUENCE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2024 (before its estimated June 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-08-14; most recent amendment 2024-10-17.
Status change: Recruiting → Active, Not Recruiting 2022-10-10
Status change: Not Yet Recruiting → Recruiting 2018-11-22
Trial Details
NCT Number NCT03635021
Lead Sponsor Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborators: Amgen
Conditions Colorectal Cancer
Enrollment 419 participants
Start Date 2018-10-15
Primary Completion 2025-06-28 (estimated)
Study Completion 2025-06-28 (estimated)
Updated on ClinicalTrials.gov 2024-10-21